Zacks: Analysts Anticipate Mirum Pharmaceuticals (NASDAQ:MIRM) Will Post Earnings of -$0.85 Per Share

Brokerages expect Mirum Pharmaceuticals (NASDAQ:MIRM) to report ($0.85) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Mirum Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.83) and the lowest estimate coming in at ($0.86). The business is scheduled to report its next quarterly earnings report on Wednesday, February 5th.

According to Zacks, analysts expect that Mirum Pharmaceuticals will report full-year earnings of ($4.84) per share for the current fiscal year. For the next fiscal year, analysts forecast that the business will report earnings of ($3.36) per share, with EPS estimates ranging from ($3.49) to ($3.22). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Mirum Pharmaceuticals.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, November 6th. The company reported ($0.84) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.25).

Several brokerages have commented on MIRM. Zacks Investment Research downgraded Mirum Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Citigroup began coverage on Mirum Pharmaceuticals in a report on Monday, August 12th. They set a “buy” rating and a $21.00 target price on the stock. Roth Capital began coverage on Mirum Pharmaceuticals in a report on Monday, August 12th. They set a “buy” rating and a $33.00 target price on the stock. Evercore ISI began coverage on Mirum Pharmaceuticals in a research report on Monday, August 12th. They issued an “outperform” rating and a $25.00 price objective for the company. Finally, Raymond James began coverage on Mirum Pharmaceuticals in a research report on Monday, August 12th. They issued an “outperform” rating and a $28.00 price objective for the company. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $22.25.

In related news, SVP Ian Clements purchased 4,000 shares of the business’s stock in a transaction on Friday, September 6th. The stock was acquired at an average price of $11.51 per share, for a total transaction of $46,040.00. Also, Director Laurent Fischer purchased 4,650 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were bought at an average price of $10.60 per share, with a total value of $49,290.00. Insiders purchased a total of 21,432 shares of company stock valued at $232,684 over the last ninety days.

A hedge fund recently bought a new stake in Mirum Pharmaceuticals stock. Dean Capital Investments Management LLC bought a new position in Mirum Pharmaceuticals (NASDAQ:MIRM) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 45,420 shares of the company’s stock, valued at approximately $457,000. Dean Capital Investments Management LLC owned about 0.20% of Mirum Pharmaceuticals at the end of the most recent quarter. 18.42% of the stock is owned by hedge funds and other institutional investors.

MIRM traded up $0.22 during midday trading on Friday, hitting $7.41. 65,300 shares of the company were exchanged, compared to its average volume of 46,748. Mirum Pharmaceuticals has a 1-year low of $6.80 and a 1-year high of $15.50. The business has a 50 day moving average price of $8.37. The company has a current ratio of 11.85, a quick ratio of 7.64 and a debt-to-equity ratio of 0.01.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).

Read More: What are some reasons analysts would give stocks a buy rating?

Get a free copy of the Zacks research report on Mirum Pharmaceuticals (MIRM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.